We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Great Lakes Pharmaceuticals Announces Initiation of Clinical Trial of B-Lock™

News   Jul 31, 2012

 
Great Lakes Pharmaceuticals Announces Initiation of Clinical Trial of B-Lock™
 
 
 

RELATED ARTICLES

Antibody Therapy That Trains Phagocytes to Destroy Tumors Is Tested in Patients

News

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.

READ MORE

“Smart Drug” Shows Promise for Metastatic Triple-Negative Breast Cancer

News

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers.

READ MORE

Drug Combo Could Become New Standard Treatment for Advanced Kidney Cancer

News

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a Phase 3 clinical trial.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE